Oral anti-diabetic drugs

DRUG3 trials

Sponsors

Seoul National University Hospital, Sanofi

Conditions

Partial Pancreatectomy Due to Benign Pancreatic NeoplasmType 2 Diabetes Mellitus

Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

CompletedNCT02749890

SanofiType 2 Diabetes Mellitus

Start: 2016-05-09End: 2018-05-31Updated: 2020-06-16

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

CompletedNCT02752828

SanofiType 2 Diabetes Mellitus

Start: 2016-05-23End: 2018-03-12Updated: 2020-06-16

Unknown Phase

Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.

Seoul National University HospitalPartial Pancreatectomy Due to Benign Pancreatic Neoplasm

Start: 2008-05-31End: 2017-12-31Updated: 2015-11-20

Related Papers

Benefits of the fixed‐ratio combination of insulin glargine 100 units/ <scp>mL</scp> and lixisenatide ( <scp>iGlarLixi</scp> ) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the <scp>LixiLan JP</scp> phase 3 trials

Diabetes Obesity and Metabolism2020-07-067 citations

Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26‐week, open‐label, multicentre study: The <scp>LixiLan JP‐O2</scp> randomized clinical trial

Diabetes Obesity and Metabolism2020-04-1535 citations

Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, after Distal Pancreatectomy

Cell Transplantation2014-07-0110 citations